ClinicalTrials.gg
Not yet recruitingNCT05105321CDPPUpdated Nov 3, 2021

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

A Phase 4 interventional study of Berberine and Healthy lifestyle intervention in Metabolic Syndrome, sponsored by Tang Yida. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-03.

Sponsored by Tang Yida · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5,200
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing berberine in Metabolic Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Berberine · Metabolic Syndrome.

Planned enrollment
Largest of 10
5,200 · median 53
Started
2021
with 2 others
Phase 4
2 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Tang Yida

Among the 10 studies testing berberine in Metabolic Syndrome, this one has the largest planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 4, and was the 9th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

2 of the 10 studies testing berberine in Metabolic Syndrome are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About berberine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing berberine in Metabolic Syndrome, or all of them as a file.
02

Study summary

The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).

Read the detailed description

Metabolic syndrome (MS) is a condition with multiple abnormal metabolic components, including obesity, dysglycemia, dyslipidemia and hypertension. The components of metabolic syndrome are major risk factors for cardiovascular disease and diabetes. Cardiovascular disease (CVD) is the primary cause of death and disease burden in China. This study aims to explore an intervention drug that can effectively control a variety of risk factors (hyperglycemia, dyslipidemia, hypertension), so as to improve the effectiveness and practical feasibility of primary prevention. Berberine is a drug with multiple function. Basic studies and previous clinical studies suggest that it has definite regulatory effects on blood glucose, lipid levels and blood pressure with few adverse reactions. This study selected pleiotropic Berberine as a means of intervention. It would provide new thought and high-level evidence for the primary prevention of cardiovascular disease and diabetes in Chinese population.

03

Conditions studied

  • Metabolic Syndrome

Keywords

  • Berberine
  • Cardiovascular Diseases
  • Diabetes
  • Metabolic Syndrome
  • Primary Prevention
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with metabolic syndrome aged 40-75 years old.
  • Metabolic syndrome was defined according to the Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults (revised edition 2016). Subjects will be diagnosed with metabolic syndrome when meeting three or more of the following items: 1, central obesity and/or abdominal obesity (waist circumference ≥90cm for men and ≥ 85cm for women); 2, hyperglycemia (fasting blood glucose ≥6.10 mmol/L or two-hour blood glucose ≥7.80 mmol/L in glucose tolerance test); 3, hypertension: blood pressure ≥130/85 mmHg and/or diagnosed hypertension under treatment; 4, fasting triglyceride ≥1.7 mmol/L (150mg/dl); 5, fasting HDL cholesterol\<1.0 mmol/L.

Exclusion criteria

Exclusion Criteria:

  • Previously diagnosed diabetes.
  • Baseline LDL cholesterol≥130mg/dl (3.4mmol/L).
  • Baseline triglyceride≥500mg/dl (5.6mmol/L).
  • Baseline blood pressure ≥140/90 mmHg (twice not on the same day).
  • Impaired liver function, have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, alanine/ levels >3 times the upper limit of the reference range at the screening visit.
  • Renal dysfunction (\<45ml/min)
  • Patients ventilated by ventilator.
  • to berberine.
  • Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic respiratory disease).
  • Severe chronic gastrointestinal disease.
  • Severe psychiatric illness.
  • Cancer requiring treatment in past 5 years.
  • Women who are pregnant or breastfeeding .
  • Participation in another clinical trial within the past 30 days .
  • Other significant disease that in the Investigator's opinion would exclude the subject from the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
5,200 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Group

    Placebo plus healthy lifestyle intervention. Placebo with same appearance of berberine tablet will be orally taken twice daily and maintained until the last subject completes 3-year intervention.

    Behavioral: Healthy lifestyle intervention

  • Experimental
    Berberine Group

    Berberine plus healthy lifestyle intervention. Berberine dose is 500mg twice daily and maintained until the last subject completes 3-year intervention.

    Drug: Berberine · Behavioral: Healthy lifestyle intervention

Interventions

  • The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily

    Also known as: berberine hydrochloride

  • BehavioralHealthy lifestyle intervention

    Healthy lifestyle intervention will be launched according to the "Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019", including health lectures, health information promotion, health manual and so on.

06

What researchers measure

Primary outcomes

  1. Rate of composite cardiometabolic endpoints

    The composite endpoints including cardiac death, nonfatal myocardial infarction, nonfatal stroke, and newly-diagnosed type 2 diabetes.

    Time frame: three year

Secondary outcomes

  1. Rate of composite endpoints of cardiovascular diseases 1

    The composite endpoints including cardiac death, nonfatal myocardial infarction, nonfatal stroke.

    Time frame: three year

  2. Rate of composite end point of cardiovascular disease 2

    The composite endpoints including cardiac death, nonfatal myocardial infarction, nonfatal stroke, successful resuscitation of cardiac arrest, heart failure, arterial revascularization.

    Time frame: three year

  3. Rates of each component of the composite end point

    Each component of the composite end point

    Time frame: three year

  4. Rate of all-cause mortality

    Death due to all causes.

    Time frame: three year

  5. Rate of newly diagnosed prediabetes

    Prediabetes including impaired fasting glucose and abnormal glucose tolerance.

    Time frame: three year

  6. Rate of newly diagnosed hypertension

    Hypertension is defined as blood pressure≥140/90 millimeters of mercury measured twice at not same day.

    Time frame: three year

  7. Rate of newly diagnosed malignancy

    Newly diagnosed malignancy.

    Time frame: three year

  8. Concentrations of serum lipid parameters

    Serum lipid parameters including total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, Lp(a).

    Time frame: three year

  9. Changes of abdominal circumference

    Measurement of abdominal circumference in centimeter

    Time frame: three year

  10. Changes of waist-hip ratio

    Measurement of waist-hip ratio

    Time frame: three year

  11. Changes of body mass index

    Measurement of body mass index in kg/m\^2

    Time frame: three year

07

Study locations

1 site
08

References and documents

Publications

  • Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414. doi: 10.1016/j.jacc.2019.03.009. Epub 2019 Mar 17. Erratum In: J Am Coll Cardiol. 2019 Sep 10;74(10):1428-1429. doi: 10.1016/j.jacc.2019.07.010. J Am Coll Cardiol. 2020 Feb 25;75(7):840. doi: 10.1016/j.jacc.2019.12.015. PubMed 30894319 ↗
  • Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004 Dec;10(12):1344-51. doi: 10.1038/nm1135. Epub 2004 Nov 7. PubMed 15531889 ↗
  • Chang W, Chen L, Hatch GM. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol. 2015 Oct;93(5):479-86. doi: 10.1139/bcb-2014-0107. Epub 2014 Dec 1. PubMed 25607236 ↗

Individual participant data

Plan to share: No — The data, analytic methods, and study materials will not be made available immediately to other researchers. The reason for the lack of availability is that we have signed an agreement with the sponsor to restrict approach to study data, and the access must be agreed by both investigator and sponsor. Request to get these materials can be sent to the corresponding author, and we will provide them to vetted and qualified applicants.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2021; primary completion for Dec 2026, 60 months later.

Of 32 phase 4 interventional studies under Metabolic Syndrome, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2021
First posted
Nov 3, 2021
StartEst.
Dec 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Nov 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05105321
Lead sponsor
Tang Yida
Collaborators
Chinese Society of Cardiology
Responsible party
Tang Yida (Chief-Cardiologist and Director, Peking University Third Hospital) — Sponsor-investigator
First posted
Nov 3, 2021
Start date
Dec 2021 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 3, 2021

Study contacts

Wenyao Wang, MD, PhD
Contact
wwypumc@126.com
0086-18810488381
Yi-Da Tang, MD, PhD
principal investigator · Peking University Third Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berberine

Start the discussion